Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Sorry, there are no financial reports available yet.

Investor presentations

Wedbush Presentation August 2019 in NYC

ObsEva_Wedbush-August2019_FinalDownload

KOL Event in NYC July 2019

KOL Event July 2019-FINAL_Jul18Download

Jefferies Healthcare Conference Presentation – June 2019

ObsEva_June2019.pdfDownload

ObsEva Short Report 2018

ObsEva_Short_Report_Final_2019_03_06 (2)Download
1 2 3

Press Releases

ObsEva SA to Attend Jefferies Healthcare Conference in NYC

press release

May 31, 2017

Geneva, Switzerland and Boston, MA – 31 May 2017 – ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics…

Read more

ObsEva Reports First Quarter 2017 Financial Results and Business Update

press release

May 18, 2017

– Phase 3 Programs Underway in Uterine Fibroids and Assisted Reproduction Technology (ART) – Geneva, Switzerland and Boston, MA – May 18, 2017 – ObsEva SA (NASDAQ:…

Read more

ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022

press release

– OBE022 is ObsEva’s potential first-in-class, oral and selective PGF2alpha receptor antagonist for the treatment of preterm labor – Geneva, Switzerland and Boston, MA – 18…

Read more
1 … 74 75 76 77 78 … 87

General Meetings

ObsEva Annual General Meeting 2023

June 29, 2023

Read more

ObsEva Annual General Meeting 2022

May 18, 2022

Read more
1 2 3 4

Upcoming Events

Annual General Meeting: Thursday 27 June, 2024

Event


    Read more
     

    Stock Information

    Latest Press Release

    ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listing

    Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 –…

    Read more

    Investor Contact


    IR@obseva.ch

    Media Contact

    Media

    contact@obseva.ch

    Contacts

    ObsEva Switzerland Office

    Chemin des Aulx,12

    1228, Plan-Les-Ouates, Geneva, Switzerland

    +41 (0)22 552 3840


    contact@obseva.ch

    Media

    contact@obseva.ch

    Investor relations


    IR@obseva.ch

    CEO Office

    +41 (0)22 552 1550


    contact@obseva.ch

     

    Sign up for news

     
     

      * Type:


      InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












      Read our privacy policy here.


       

      Are you sure you want to leave ObsEva.com?

      We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

      Continue to link

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue